Hospital
Knox Community Hospital
Knox Community Hospital was paid $29.19M by Medicaid between Jan 2018 and Dec 2024, across 338 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 17% of everything it billed.
33Billing provider infoKNOX COMMUNITY HOSPITAL
MOUNT VERNON, OH 43050
MOUNT VERNON, OH 43050
33aNPI1295761963assigned 06/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.19M
24GClaims749,389
24DCodes billed338
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#39 of 101
Median peer was paid$22.32M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,030 | $2.77M | |
| 2019 | 87,273 | $2.90M | |
| 2020 | 70,643 | $3.66M | |
| 2021 | 82,724 | $3.98M | |
| 2022 | 82,658 | $3.59M | |
| 2023 | 201,415 | $6.88M | |
| 2024incomplete | 130,646 | $5.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 62,737 | 56,131 | $5.08M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 17% | 64,330 | 57,198 | $4.86M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 22,712 | 20,962 | $2.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 20,044 | 18,755 | $2.33M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.9% | 46,404 | 40,451 | $1.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 10,150 | 8,906 | $1.25M |
| 31231 | 2.5% | 3,890 | 3,473 | $738K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 1,992 | 1,709 | $593K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.0% | 7,256 | 2,666 | $582K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 8,759 | 2,264 | $522K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 2,251 | 2,010 | $475K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.6% | 5,117 | 4,374 | $464K |
326 more codes
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.6% | 1,118 | $461K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 3,463 | $449K |
| 20610 | 1.4% | 2,748 | $408K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 2,997 | $347K |
| 80053 | Comprehensive metabolic panel | 1.1% | 34,535 | $335K |
| 95811 | <1% | 607 | $270K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 936 | $269K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,064 | $262K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,086 | $232K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 549 | $216K |
| 95117 | <1% | 7,968 | $194K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 901 | $169K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 547 | $163K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,679 | $152K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,559 | $126K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,271 | $125K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,569 | $112K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 437 | $111K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 18,788 | $106K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 888 | $105K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,895 | $102K |
| 51798 | <1% | 3,832 | $101K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 822 | $99K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,539 | $98K |
| 59025 | Fetal non-stress test | <1% | 548 | $97K |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,220 | $94K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,236 | $84K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,373 | $79K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 294 | $75K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 612 | $69K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,426 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,003 | $62K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 190 | $62K |
| G0378 | Hospital observation service, per hour | <1% | 963 | $62K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,536 | $60K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 496 | $59K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,623 | $56K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 491 | $54K |
| 80061 | Lipid panel | <1% | 3,212 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,890 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,101 | $47K |
| 86900 | <1% | 1,839 | $46K | |
| 31575 | <1% | 237 | $44K | |
| 97161 | <1% | 830 | $41K | |
| 70486 | <1% | 374 | $40K | |
| 84439 | <1% | 2,446 | $39K | |
| 59430 | <1% | 499 | $38K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 387 | $37K |
| 31237 | <1% | 86 | $37K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,118 | $36K |
| 83970 | <1% | 1,140 | $35K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 293 | $35K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 403 | $33K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,089 | $33K |
| 84484 | <1% | 8,085 | $33K | |
| 85027 | <1% | 5,558 | $32K | |
| 76801 | <1% | 384 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,628 | $30K |
| 88142 | <1% | 1,933 | $30K | |
| 82607 | <1% | 1,549 | $28K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,806 | $27K |
| 76536 | <1% | 258 | $26K | |
| 76830 | Ultrasound, transvaginal | <1% | 237 | $26K |
| 87806 | <1% | 699 | $26K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 759 | $26K |
| 86850 | <1% | 1,772 | $25K | |
| 76642 | <1% | 189 | $24K | |
| 73564 | <1% | 1,923 | $24K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,868 | $22K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,299 | $21K |
| 52000 | <1% | 33 | $21K | |
| 97165 | <1% | 361 | $20K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 630 | $20K |
| 80320 | <1% | 1,620 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,324 | $20K |
| 99223 | Prolong inpt eval add15 m | <1% | 405 | $19K |
| 81001 | <1% | 15,360 | $19K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,055 | $19K |
| 83735 | <1% | 9,259 | $18K | |
| 92557 | <1% | 407 | $17K | |
| 93017 | <1% | 246 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 702 | $16K |
| 84481 | <1% | 1,023 | $16K | |
| 86803 | <1% | 825 | $16K | |
| 83655 | <1% | 676 | $16K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 106 | $15K |
| 76770 | <1% | 119 | $15K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 823 | $14K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 111 | $14K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,578 | $13K |
| 0002A | <1% | 355 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 321 | $13K |
| 86901 | <1% | 1,721 | $12K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 68 | $12K |
| 0001A | <1% | 376 | $12K | |
| 99406 | <1% | 940 | $12K | |
| 82728 | <1% | 899 | $12K | |
| 71250 | <1% | 144 | $12K | |
| 97162 | <1% | 298 | $11K | |
| 73630 | <1% | 1,087 | $11K | |
| 90715 | <1% | 603 | $11K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 446 | $11K |
| 85610 | <1% | 5,229 | $11K | |
| 74018 | <1% | 601 | $11K | |
| 73030 | <1% | 851 | $11K | |
| 93971 | <1% | 157 | $10K | |
| 90686 | <1% | 1,120 | $10K | |
| 84100 | <1% | 1,634 | $10K | |
| 86140 | <1% | 769 | $9K | |
| 84153 | <1% | 546 | $9K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 379 | $9K |
| 83550 | <1% | 866 | $9K | |
| 84450 | <1% | 1,021 | $9K | |
| 92567 | <1% | 560 | $9K | |
| 73130 | <1% | 858 | $9K | |
| 94060 | <1% | 177 | $8K | |
| 96127 | <1% | 147 | $8K | |
| 87340 | <1% | 530 | $8K | |
| 94729 | <1% | 157 | $8K | |
| 97113 | <1% | 177 | $8K | |
| 70496 | <1% | 30 | $8K | |
| 69210 | <1% | 562 | $8K | |
| 80076 | <1% | 521 | $8K | |
| 84702 | <1% | 1,099 | $8K | |
| 93225 | <1% | 106 | $8K | |
| 83540 | <1% | 952 | $8K | |
| 72100 | <1% | 230 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 236 | $7K |
| 73610 | <1% | 938 | $7K | |
| 73110 | <1% | 662 | $7K | |
| 97116 | <1% | 262 | $7K | |
| 93922 | <1% | 88 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,537 | $6K |
| 95886 | <1% | 84 | $6K | |
| 86592 | <1% | 395 | $6K | |
| 82570 | <1% | 732 | $6K | |
| 83605 | <1% | 1,697 | $6K | |
| 73502 | <1% | 425 | $6K | |
| 92587 | <1% | 252 | $6K | |
| 84460 | <1% | 1,037 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 725 | $5K |
| 84156 | <1% | 659 | $5K | |
| 87077 | <1% | 1,696 | $5K | |
| 87186 | <1% | 1,696 | $5K | |
| 87070 | <1% | 1,002 | $5K | |
| 93970 | <1% | 29 | $5K | |
| 96376 | <1% | 1,305 | $5K | |
| 83690 | <1% | 8,868 | $5K | |
| 84403 | <1% | 330 | $4K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 300 | $4K |
| 82043 | <1% | 694 | $4K | |
| 86762 | <1% | 309 | $4K | |
| 84402 | <1% | 222 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 117 | $4K |
| 73560 | <1% | 490 | $4K | |
| 86038 | <1% | 280 | $4K | |
| 93226 | <1% | 109 | $4K | |
| 82565 | <1% | 635 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 105 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 131 | $4K |
| 85007 | <1% | 1,427 | $4K | |
| 82948 | <1% | 1,980 | $4K | |
| 82950 | <1% | 300 | $4K | |
| 51741 | <1% | 835 | $4K | |
| 94726 | <1% | 130 | $4K | |
| 86787 | <1% | 292 | $4K | |
| 81025 | <1% | 2,077 | $3K | |
| 85652 | <1% | 780 | $3K | |
| 84703 | <1% | 2,684 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 98 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,341 | $3K |
| 81003 | <1% | 5,307 | $3K | |
| 73620 | <1% | 530 | $3K | |
| 11720 | <1% | 175 | $3K | |
| 93296 | <1% | 263 | $3K | |
| 85014 | <1% | 542 | $3K | |
| 72110 | <1% | 172 | $3K | |
| 70498 | <1% | 50 | $3K | |
| 86200 | <1% | 79 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $3K |
| 87631 | <1% | 69 | $3K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 102 | $2K |
| 93299 | <1% | 101 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 14 | $2K |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 20 | $2K |
| 87081 | <1% | 309 | $2K | |
| 73221 | <1% | 12 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,151 | $2K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 224 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,682 | $2K |
| 86003 | <1% | 176 | $2K | |
| 12001 | <1% | 16 | $2K | |
| 82040 | <1% | 190 | $2K | |
| 85018 | <1% | 555 | $2K | |
| 85730 | <1% | 3,989 | $2K | |
| 84550 | <1% | 360 | $2K | |
| 85379 | <1% | 916 | $2K | |
| 99217 | <1% | 75 | $2K | |
| 80329 | <1% | 219 | $2K | |
| 84436 | <1% | 1,211 | $2K | |
| 83880 | <1% | 798 | $1K | |
| 82746 | <1% | 150 | $1K | |
| 99220 | <1% | 34 | $1K | |
| 76827 | <1% | 111 | $1K | |
| 76937 | <1% | 63 | $1K | |
| 0004A | <1% | 36 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,327 | $1K |
| 72131 | <1% | 29 | $1K | |
| 72072 | <1% | 54 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,756 | $1K |
| 90656 | <1% | 155 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 55 | $1K |
| 88304 | <1% | 218 | $1K | |
| 73590 | <1% | 79 | $1K | |
| 82550 | <1% | 365 | $1K | |
| 97802 | <1% | 13 | $1K | |
| 88341 | <1% | 19 | $973.38 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,152 | $944.93 |
| 80349 | <1% | 44 | $931.59 | |
| 80361 | <1% | 27 | $915.34 | |
| 87040 | <1% | 770 | $909.09 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,009 | $879.23 |
| 82652 | <1% | 52 | $810.76 | |
| 84146 | <1% | 39 | $809.31 | |
| 86376 | <1% | 47 | $799.69 | |
| 83615 | <1% | 184 | $781.03 | |
| 86705 | <1% | 47 | $745.90 | |
| 95909 | <1% | 12 | $720.73 | |
| 73140 | <1% | 61 | $666.87 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,209 | $646.03 |
| 93976 | <1% | 19 | $644.03 | |
| 86709 | <1% | 46 | $625.94 | |
| 83001 | <1% | 40 | $611.04 | |
| 82670 | <1% | 37 | $605.02 | |
| 77066 | Tomosynthesis, mammo | <1% | 26 | $585.07 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,472 | $554.59 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 652 | $536.55 |
| 99152 | <1% | 51 | $506.85 | |
| Q3014 | Telehealth originating site facility fee | <1% | 75 | $489.97 |
| 86431 | <1% | 40 | $488.42 | |
| 82140 | <1% | 127 | $474.64 | |
| 91035 | <1% | 122 | $446.35 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 141 | $439.74 |
| 80358 | <1% | 27 | $433.22 | |
| 83883 | <1% | 15 | $401.40 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,018 | $395.06 |
| 83516 | <1% | 14 | $377.80 | |
| 80324 | <1% | 27 | $356.23 | |
| 80346 | <1% | 27 | $356.22 | |
| 80345 | <1% | 27 | $356.22 | |
| 87481 | <1% | 12 | $332.00 | |
| 82951 | <1% | 12 | $328.32 | |
| 80306 | <1% | 325 | $321.23 | |
| 69209 | <1% | 32 | $319.49 | |
| 00731 | <1% | 133 | $317.69 | |
| 86703 | <1% | 37 | $304.43 | |
| 86618 | <1% | 29 | $302.61 | |
| 72052 | <1% | 12 | $295.49 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,186 | $287.10 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 92 | $270.59 |
| 86800 | <1% | 16 | $260.38 | |
| 82784 | <1% | 14 | $246.24 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 652 | $233.76 |
| 80353 | <1% | 27 | $216.60 | |
| 73080 | <1% | 14 | $204.34 | |
| 86706 | <1% | 16 | $200.05 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 624 | $185.71 |
| 82248 | <1% | 30 | $182.91 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,311 | $172.09 |
| 71101 | <1% | 25 | $170.19 | |
| 84207 | <1% | 13 | $168.50 | |
| 11721 | <1% | 14 | $166.97 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,177 | $160.70 |
| 99490 | Ccm add 20min | <1% | 403 | $159.23 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,464 | $156.96 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 204 | $148.10 |
| 73070 | <1% | 13 | $145.95 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 362 | $140.42 |
| 72040 | <1% | 14 | $131.94 | |
| 84425 | <1% | 12 | $131.53 | |
| 80366 | <1% | 29 | $116.41 | |
| G0008 | Administration of influenza virus vaccine | <1% | 132 | $111.46 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,107 | $99.94 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 639 | $93.46 |
| 87147 | <1% | 34 | $91.71 | |
| 82150 | <1% | 76 | $88.51 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,168 | $72.76 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,550 | $65.93 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,117 | $63.17 |
| 85055 | <1% | 19 | $62.86 | |
| 82800 | <1% | 67 | $53.92 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 34 | $37.82 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 168 | $29.36 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 82 | $26.92 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 56 | $25.99 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,108 | $23.08 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 65 | $22.92 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 22 | $18.60 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 55 | $16.05 |
| 87075 | <1% | 16 | $15.36 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 48 | $14.87 |
| 90670 | <1% | 77 | $10.98 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 366 | $9.84 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 15 | $8.84 |
| 91300 | <1% | 800 | $7.57 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 63 | $6.60 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 59 | $4.08 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 56 | $2.56 |
| 94760 | <1% | 1,856 | $1.19 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 169 | $0.31 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 80 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 76 | $0.00 |
| 87400 | 0% | 14 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 13 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 203 | $0.00 |
| 80143 | 0% | 15 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 331 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 17 | $0.00 |
| 00840 | 0% | 19 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 108 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 130 | $0.00 |
| 73090 | 0% | 15 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 24 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| 00160 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialO'BRIEN, DANIELLE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Knox Community Hospital | Mount Vernon, OH | $5.70M |
| Knox Community Hospital | Mount Vernon, OH | $113K |
| Knox Community Hospital | Mount Vernon, OH | $31K |
| Knox Community Hospital | Mount Vernon, OH | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.